Pfizer India and Cipla Limited has announced a partnership where Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory ...

The Justice Department released thousands of documents from its "Epstein library," including photos of former President Bill Clinton and other celebrities. Many of the released documents are heavily ...

WASHINGTON ― Previously stashed-away pictures of former President Bill Clinton and other celebrities have found their way into the Justice Department's coveted "Epstein library." The Dec. 19 release ...

Pfizer India and Cipla announced a partnership on Friday in which Cipla will exclusively market and distribute four Pfizer brands in India to increase their reach. The first partnership between Pfizer ...

Pfizer India and Cipla Limited on Friday announced a partnership where Cipla will exclusively market and distribute four brands of Pfizer in India. Under the agreement, Cipla now has the sole right to ...

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits Yearly Premium ₹999 ₹349/Year SUBSCRIBE NOW Under the ...

This article first appeared on GuruFocus. Pfizer (NYSE:PFE) shares slid about 5% on Tuesday morning after the company lowered its earnings and revenue forecasts for 2026. The pharmaceutical giant now ...

Pfizer Inc. (NYSE: PFE) is scheduled to provide its full-year 2026 financial guidance on Tuesday, with Bank of America Securities expecting the company's growth profile to closely resemble conditions ...

NEW YORK, December 12, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company’s common stock, payable ...

Deal marks Pfizer's re-entry into obesity treatment market Pfizer shares rise 1.4%, Novo Nordisk falls 1.3% Metsera candidate MET-097i advances to late-stage trials The greenlight from Metsera's ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, capping a whirlwind two weeks in which rival pharma Novo Nordisk attempted to ...

Pfizer has won a $10 billion deal to acquire the fast-rising obesity drug developer Metsera, ending a fierce bidding war with Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer ...